|
|
Article: Trial assesses Actos in cardiovascular disease progression and type 2 diabetes.
- Article from:
- Biotech Business Week
- Article date:
- July 26, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 JUL 26 - (NewsRx.com & NewsRx.net) -- In the July 2004 issue of Diabetes Care, researchers published the study design and baseline characteristics of patients enrolled in the landmark PROspective PioglitAzone Clinical Trial In MacroVascular Events Study (PROactive).
PROactive is a European clinical trial assessing the effects of Actos (pioglitazone HCl) on mortality and morbidity associated with cardiovascular
disease progression in patients with type 2 diabetes.
The study has enrolled 5,238 patients in 19 countries who have experienced one or more cardiovascular events such as a heart attack, coronary artery bypass surgery, or stroke.
...